| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 24 | 2025 | 260 | 10.410 |
Why?
|
| Early Detection of Cancer | 19 | 2025 | 513 | 4.390 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2025 | 246 | 3.700 |
Why?
|
| Telemedicine | 7 | 2023 | 186 | 2.650 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 50 | 2.620 |
Why?
|
| Neoplasms | 12 | 2023 | 444 | 2.530 |
Why?
|
| Health Care Costs | 8 | 2019 | 229 | 2.290 |
Why?
|
| Humans | 98 | 2025 | 17762 | 2.290 |
Why?
|
| Breast Neoplasms | 11 | 2021 | 954 | 2.270 |
Why?
|
| Colorectal Neoplasms | 10 | 2022 | 615 | 1.770 |
Why?
|
| Aged | 42 | 2025 | 6150 | 1.770 |
Why?
|
| Neoplasm Staging | 11 | 2025 | 327 | 1.640 |
Why?
|
| Electronic Health Records | 9 | 2024 | 697 | 1.590 |
Why?
|
| Middle Aged | 48 | 2025 | 7988 | 1.510 |
Why?
|
| Delivery of Health Care | 8 | 2023 | 415 | 1.480 |
Why?
|
| Female | 51 | 2025 | 12740 | 1.400 |
Why?
|
| Male | 48 | 2025 | 10106 | 1.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 46 | 1.340 |
Why?
|
| Retrospective Studies | 23 | 2025 | 2461 | 1.320 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 1923 | 1.310 |
Why?
|
| Health Maintenance Organizations | 12 | 2014 | 417 | 1.310 |
Why?
|
| Adult | 34 | 2023 | 7678 | 1.240 |
Why?
|
| United States | 29 | 2025 | 4003 | 1.190 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 59 | 1.150 |
Why?
|
| Algorithms | 5 | 2018 | 239 | 1.150 |
Why?
|
| Mass Screening | 8 | 2025 | 677 | 1.070 |
Why?
|
| Internet | 6 | 2014 | 231 | 1.030 |
Why?
|
| Deductibles and Coinsurance | 2 | 2023 | 30 | 0.960 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 6 | 0.960 |
Why?
|
| Malnutrition | 1 | 2023 | 2 | 0.880 |
Why?
|
| Clinical Coding | 3 | 2018 | 11 | 0.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2011 | 755 | 0.800 |
Why?
|
| Colorado | 14 | 2023 | 164 | 0.790 |
Why?
|
| Population Dynamics | 1 | 2021 | 6 | 0.770 |
Why?
|
| Medicare | 7 | 2023 | 205 | 0.770 |
Why?
|
| Self Care | 3 | 2012 | 163 | 0.760 |
Why?
|
| Preventive Medicine | 1 | 2021 | 24 | 0.760 |
Why?
|
| Pandemics | 8 | 2023 | 287 | 0.750 |
Why?
|
| Bevacizumab | 3 | 2016 | 8 | 0.750 |
Why?
|
| Smoking Cessation | 6 | 2009 | 193 | 0.740 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 210 | 0.730 |
Why?
|
| Natural Language Processing | 1 | 2021 | 58 | 0.710 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 108 | 0.700 |
Why?
|
| Health Services | 3 | 2018 | 112 | 0.690 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 2 | 0.670 |
Why?
|
| Models, Organizational | 1 | 2019 | 55 | 0.670 |
Why?
|
| Electronic Mail | 3 | 2021 | 51 | 0.670 |
Why?
|
| Melanoma | 1 | 2019 | 35 | 0.640 |
Why?
|
| Patient Selection | 5 | 2013 | 190 | 0.630 |
Why?
|
| Smoking | 4 | 2023 | 483 | 0.630 |
Why?
|
| Cohort Studies | 11 | 2022 | 2586 | 0.620 |
Why?
|
| Managed Care Programs | 5 | 2009 | 325 | 0.610 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 57 | 0.610 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 328 | 0.610 |
Why?
|
| Diagnostic Imaging | 3 | 2017 | 45 | 0.600 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 61 | 0.590 |
Why?
|
| Costs and Cost Analysis | 5 | 2018 | 80 | 0.590 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 262 | 0.590 |
Why?
|
| Primary Health Care | 8 | 2024 | 769 | 0.580 |
Why?
|
| Patient Care Management | 1 | 2017 | 30 | 0.580 |
Why?
|
| Population Surveillance | 6 | 2017 | 264 | 0.570 |
Why?
|
| Health Promotion | 3 | 2009 | 281 | 0.540 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 17 | 0.530 |
Why?
|
| Public Health Informatics | 3 | 2005 | 7 | 0.530 |
Why?
|
| Health Behavior | 4 | 2014 | 360 | 0.520 |
Why?
|
| Obesity | 4 | 2023 | 842 | 0.520 |
Why?
|
| Weight Loss | 3 | 2013 | 305 | 0.500 |
Why?
|
| Young Adult | 10 | 2019 | 2461 | 0.490 |
Why?
|
| Patient Compliance | 4 | 2025 | 300 | 0.490 |
Why?
|
| SEER Program | 5 | 2019 | 91 | 0.480 |
Why?
|
| Guideline Adherence | 4 | 2025 | 157 | 0.480 |
Why?
|
| Treatment Outcome | 9 | 2016 | 1260 | 0.480 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 1213 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 24 | 0.460 |
Why?
|
| Hispanic Americans | 3 | 2011 | 404 | 0.450 |
Why?
|
| Hormones | 1 | 2013 | 14 | 0.440 |
Why?
|
| Drug Therapy | 1 | 2013 | 18 | 0.440 |
Why?
|
| Lung | 3 | 2024 | 62 | 0.430 |
Why?
|
| Firearms | 2 | 2024 | 32 | 0.430 |
Why?
|
| Influenza, Human | 3 | 2015 | 265 | 0.420 |
Why?
|
| Physical Fitness | 1 | 2013 | 73 | 0.420 |
Why?
|
| Patient Education as Topic | 5 | 2010 | 212 | 0.420 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 3 | 0.420 |
Why?
|
| Community Health Centers | 1 | 2013 | 64 | 0.410 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 52 | 0.410 |
Why?
|
| Registries | 6 | 2018 | 472 | 0.390 |
Why?
|
| Health Personnel | 3 | 2021 | 125 | 0.390 |
Why?
|
| Asthma | 3 | 2021 | 385 | 0.380 |
Why?
|
| Age Factors | 4 | 2019 | 918 | 0.380 |
Why?
|
| Ambulatory Care | 3 | 2023 | 247 | 0.380 |
Why?
|
| Behavior Therapy | 2 | 2012 | 146 | 0.380 |
Why?
|
| Databases, Factual | 3 | 2018 | 315 | 0.360 |
Why?
|
| Disease Outbreaks | 3 | 2005 | 36 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 535 | 0.350 |
Why?
|
| Adolescent | 10 | 2024 | 3685 | 0.350 |
Why?
|
| Bioterrorism | 3 | 2005 | 5 | 0.340 |
Why?
|
| Nutrition Therapy | 1 | 2009 | 4 | 0.340 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 26 | 0.330 |
Why?
|
| Diabetic Neuropathies | 1 | 2009 | 13 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 250 | 0.330 |
Why?
|
| Behavioral Medicine | 1 | 2009 | 4 | 0.320 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 381 | 0.320 |
Why?
|
| Health Status Indicators | 3 | 2018 | 64 | 0.320 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 630 | 0.320 |
Why?
|
| Program Evaluation | 2 | 2009 | 223 | 0.320 |
Why?
|
| Life Style | 2 | 2011 | 333 | 0.320 |
Why?
|
| Cost of Illness | 2 | 2019 | 92 | 0.310 |
Why?
|
| Advertising as Topic | 2 | 2005 | 23 | 0.300 |
Why?
|
| Prevalence | 3 | 2023 | 886 | 0.300 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 273 | 0.300 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 156 | 0.300 |
Why?
|
| Genetic Testing | 2 | 2005 | 71 | 0.290 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2018 | 7 | 0.290 |
Why?
|
| Prostatic Hyperplasia | 2 | 2018 | 24 | 0.290 |
Why?
|
| Time Factors | 6 | 2021 | 1093 | 0.280 |
Why?
|
| Incidence | 2 | 2022 | 1266 | 0.280 |
Why?
|
| Insurance, Health | 3 | 2019 | 183 | 0.260 |
Why?
|
| Low Back Pain | 1 | 2006 | 54 | 0.260 |
Why?
|
| Economics, Medical | 2 | 2022 | 4 | 0.260 |
Why?
|
| Carboplatin | 2 | 2016 | 7 | 0.250 |
Why?
|
| Paclitaxel | 2 | 2016 | 9 | 0.250 |
Why?
|
| Prognosis | 2 | 2018 | 609 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 197 | 0.250 |
Why?
|
| Body Mass Index | 3 | 2023 | 964 | 0.240 |
Why?
|
| Survival Rate | 2 | 2016 | 260 | 0.240 |
Why?
|
| Medical Records Systems, Computerized | 5 | 2013 | 85 | 0.230 |
Why?
|
| Immunization Schedule | 1 | 2005 | 122 | 0.230 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 19 | 0.230 |
Why?
|
| Recurrence | 1 | 2025 | 188 | 0.230 |
Why?
|
| Research Design | 5 | 2023 | 376 | 0.230 |
Why?
|
| Forecasting | 2 | 2022 | 75 | 0.230 |
Why?
|
| Fee-for-Service Plans | 2 | 2014 | 24 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2023 | 6 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2023 | 30 | 0.220 |
Why?
|
| Risk Factors | 7 | 2018 | 3356 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 321 | 0.210 |
Why?
|
| Back Pain | 1 | 2023 | 33 | 0.210 |
Why?
|
| Cost Sharing | 1 | 2023 | 30 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 382 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2019 | 1101 | 0.200 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 124 | 0.190 |
Why?
|
| Public Health | 1 | 2022 | 81 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2020 | 146 | 0.190 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2018 | 9 | 0.190 |
Why?
|
| Counseling | 3 | 2019 | 189 | 0.190 |
Why?
|
| Personnel Management | 1 | 2021 | 3 | 0.190 |
Why?
|
| Data Collection | 5 | 2013 | 256 | 0.190 |
Why?
|
| Cell Phone | 1 | 2021 | 12 | 0.190 |
Why?
|
| Community-Based Participatory Research | 1 | 2021 | 61 | 0.190 |
Why?
|
| Overweight | 1 | 2023 | 269 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2022 | 85 | 0.180 |
Why?
|
| Evidence-Based Practice | 2 | 2021 | 46 | 0.180 |
Why?
|
| Breast | 1 | 2021 | 85 | 0.180 |
Why?
|
| Survivors | 3 | 2022 | 149 | 0.180 |
Why?
|
| Nurse-Patient Relations | 1 | 2020 | 8 | 0.170 |
Why?
|
| Organizational Culture | 1 | 2020 | 18 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2020 | 33 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 487 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 30 | 0.170 |
Why?
|
| Community Health Planning | 1 | 2019 | 19 | 0.170 |
Why?
|
| Geography | 1 | 2019 | 39 | 0.170 |
Why?
|
| Suicide | 1 | 2021 | 124 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 48 | 0.170 |
Why?
|
| Health Expenditures | 2 | 2018 | 75 | 0.170 |
Why?
|
| Text Messaging | 1 | 2020 | 29 | 0.170 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 22 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 36 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2019 | 29 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 644 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2019 | 85 | 0.160 |
Why?
|
| Communication | 1 | 2021 | 194 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 5 | 0.160 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 37 | 0.160 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 2010 | 102 | 0.160 |
Why?
|
| Motivation | 1 | 2020 | 131 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 91 | 0.160 |
Why?
|
| Child | 6 | 2024 | 2491 | 0.160 |
Why?
|
| Health Services Research | 4 | 2016 | 231 | 0.160 |
Why?
|
| Palliative Care | 1 | 2019 | 61 | 0.160 |
Why?
|
| Suicidal Ideation | 1 | 2020 | 101 | 0.160 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 102 | 0.160 |
Why?
|
| Health Facilities | 1 | 2018 | 17 | 0.160 |
Why?
|
| Mortality | 1 | 2019 | 118 | 0.150 |
Why?
|
| Patients | 1 | 2018 | 34 | 0.150 |
Why?
|
| Hypertension | 2 | 2013 | 504 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 145 | 0.150 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 1321 | 0.140 |
Why?
|
| Office Visits | 2 | 2014 | 80 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 246 | 0.140 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2017 | 228 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2017 | 671 | 0.130 |
Why?
|
| Mental Health | 2 | 2014 | 166 | 0.130 |
Why?
|
| Comorbidity | 2 | 2009 | 597 | 0.130 |
Why?
|
| Quality of Life | 1 | 2019 | 510 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 2 | 2013 | 66 | 0.120 |
Why?
|
| Telephone | 3 | 2012 | 161 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 6 | 0.120 |
Why?
|
| Reminder Systems | 1 | 2015 | 80 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2014 | 48 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 30 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 73 | 0.110 |
Why?
|
| Heart Failure | 1 | 2019 | 396 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2013 | 38 | 0.110 |
Why?
|
| Physicians | 2 | 2005 | 137 | 0.110 |
Why?
|
| Episode of Care | 1 | 2013 | 14 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2023 | 212 | 0.110 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2013 | 61 | 0.100 |
Why?
|
| Medicare Part C | 1 | 2013 | 19 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 113 | 0.100 |
Why?
|
| Hospitalization | 3 | 2015 | 808 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 31 | 0.100 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 10 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2022 | 218 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2012 | 39 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 139 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2012 | 230 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2014 | 280 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2013 | 90 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 53 | 0.090 |
Why?
|
| Outpatients | 1 | 2012 | 110 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 719 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 197 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2019 | 428 | 0.090 |
Why?
|
| Glycated Hemoglobin A | 1 | 2011 | 216 | 0.090 |
Why?
|
| Names | 1 | 2010 | 1 | 0.090 |
Why?
|
| Social Support | 1 | 2011 | 206 | 0.080 |
Why?
|
| Menu Planning | 1 | 2009 | 2 | 0.080 |
Why?
|
| Education, Nonprofessional | 1 | 2009 | 6 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2009 | 24 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2009 | 69 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 49 | 0.080 |
Why?
|
| Patient Admission | 1 | 2009 | 72 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1120 | 0.080 |
Why?
|
| Pain Management | 1 | 2009 | 58 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 16 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 14 | 0.080 |
Why?
|
| Directive Counseling | 1 | 2009 | 25 | 0.080 |
Why?
|
| Pain | 1 | 2009 | 79 | 0.080 |
Why?
|
| Genes, BRCA1 | 2 | 2005 | 8 | 0.080 |
Why?
|
| Genes, BRCA2 | 2 | 2005 | 8 | 0.080 |
Why?
|
| Continental Population Groups | 1 | 2009 | 302 | 0.070 |
Why?
|
| Mediterranean Region | 1 | 2006 | 1 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2006 | 18 | 0.070 |
Why?
|
| Decision Making | 2 | 2005 | 183 | 0.070 |
Why?
|
| Analgesics | 1 | 2006 | 27 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2006 | 190 | 0.070 |
Why?
|
| Age Distribution | 1 | 2006 | 246 | 0.060 |
Why?
|
| Anthrax | 1 | 2005 | 2 | 0.060 |
Why?
|
| Organizations, Nonprofit | 1 | 2005 | 11 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2005 | 13 | 0.060 |
Why?
|
| Postmenopause | 1 | 2006 | 242 | 0.060 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 45 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2020 | 85 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 70 | 0.060 |
Why?
|
| Health Resources | 2 | 2013 | 37 | 0.060 |
Why?
|
| Oregon | 2 | 2017 | 180 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 1524 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 132 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 710 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2004 | 6 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 1 | 2004 | 20 | 0.060 |
Why?
|
| Specialization | 1 | 2004 | 24 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 16 | 0.060 |
Why?
|
| Smoking Prevention | 1 | 2004 | 54 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2014 | 114 | 0.060 |
Why?
|
| Disease Notification | 1 | 2003 | 7 | 0.050 |
Why?
|
| Infant | 2 | 2005 | 1192 | 0.050 |
Why?
|
| Georgia | 1 | 2023 | 26 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2005 | 1419 | 0.050 |
Why?
|
| Urban Population | 1 | 2003 | 116 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 69 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 9 | 0.050 |
Why?
|
| Logistic Models | 3 | 2017 | 927 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 75 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 213 | 0.050 |
Why?
|
| Research | 1 | 2022 | 65 | 0.050 |
Why?
|
| Mammography | 2 | 2014 | 169 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2014 | 305 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2022 | 855 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 2019 | 12 | 0.040 |
Why?
|
| Occult Blood | 1 | 2020 | 154 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1279 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 256 | 0.040 |
Why?
|
| Self Efficacy | 2 | 2009 | 68 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2019 | 113 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 29 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 505 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2018 | 114 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 181 | 0.040 |
Why?
|
| Utilization Review | 1 | 1997 | 53 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 1997 | 44 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 172 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 106 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 194 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 517 | 0.030 |
Why?
|
| Tobacco | 2 | 2005 | 14 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 11 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 129 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 22 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 300 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 26 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 42 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 215 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 125 | 0.020 |
Why?
|
| Physical Examination | 1 | 2012 | 20 | 0.020 |
Why?
|
| Washington | 1 | 2013 | 382 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 253 | 0.020 |
Why?
|
| Warfarin | 1 | 2012 | 74 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2012 | 302 | 0.020 |
Why?
|
| Current Procedural Terminology | 1 | 2009 | 3 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 331 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 237 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2009 | 13 | 0.020 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 7 | 0.020 |
Why?
|
| Vaccination | 1 | 2014 | 655 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 304 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 166 | 0.020 |
Why?
|
| Patient Participation | 1 | 2010 | 134 | 0.020 |
Why?
|
| Social Environment | 1 | 2008 | 88 | 0.020 |
Why?
|
| Biomarkers | 1 | 2009 | 303 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2005 | 1 | 0.020 |
Why?
|
| Space-Time Clustering | 1 | 2005 | 3 | 0.020 |
Why?
|
| Minnesota | 1 | 2005 | 53 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2005 | 88 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 186 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 375 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 568 | 0.010 |
Why?
|
| Health Status | 1 | 1997 | 298 | 0.010 |
Why?
|